The table below shows Altimmune, Inc.'s cash flow statement by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
Line item
Q1 2026
Q1 2025
Q1 2024
Q1 2023
Q1 2022
Q1 2021
Operating cash flow
-$20.94M
-$16.84M
-$16.36M
-$19.41M
-$13.53M
-$19.57M
Capital expenditure
$21.00K
-
-
$51.00K
$9.00K
$4.21M
Investing cash flow
-$3.69M
-$5.10M
-$39.52M
$13.30M
-$9.00K
$19.16M
Dividends paid
-
-
-
-
ALT operating cash flow (10-K history)
Altimmune, Inc. reported operating cash flow of -$67.53M for fiscal year 2025. That is up 15.4% from -$79.85M in fiscal 2024. Over the 10 fiscal years shown, operating cash flow declined from -$2.32M (FY 2012) to -$67.53M. Figures come from the company's audited annual reports as filed with the SEC.